People: PDI Inc (PDII.O)

PDII.O on Consolidated Issue listed on NASDAQ Global Market

5.18USD
9 Feb 2010
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.18
Open
--
Day's High
$5.22
Day's Low
$5.11
Volume
75,890
Avg. Vol
17,091
52-wk High
$6.25
52-wk Low
$2.80

view people for:

Summary

Name Age Since Current Position
Dugan, John 73 1997 Chairman of the Board, Director of Strategic Planning
Lurker, Nancy 51 2008 Chief Executive Officer, Director
Smith, Jeffrey 62 2006 Chief Financial Officer, Executive Vice President, Treasurer
Drazner, Howard 49 2007 President - Pharmakon
Micali, Richard 52 2009 Senior Vice President - Sales Services
Kerr, David 51 2009 Senior Vice President - Business Development
Belle, Gerald 63 2009 Lead Independent Director
Pietruski, John 76 1998 Director
Vecsi, Jan 65 1998 Director
Federspiel, John 55 2001 Director
Ryan, Frank 69 2002 Director
Curti, Joseph 71 2003 Director
Sullivan, Stephen 62 2004 Director
Stover, Jack 56 2005 Director
Lubatkin, Veronica 46 2008 Director
» Insider Trading

Biographies

Name Description
Dugan, John Mr. Dugan is the founder, Chairman of the Board and Director of Strategic Planning of PDI Inc. He served as president from inception until January 1995 and as chief executive officer from inception until November 1997. In 1972, Mr. Dugan founded Dugan Communications, a medical advertising agency that later became known as Dugan Farley Communications Associates Inc. and served as its president until 1990. PDI was a wholly-owned subsidiary of Dugan Farley in 1990 when Mr. Dugan became sole stockholder. Mr. Dugan was a founder and served as the president of the Medical Advertising Agency Association from 1983 to 1984. Mr. Dugan also served on the board of directors of the Pharmaceutical Advertising Council (now known as the Healthcare Marketing Communications Council, Inc.) and was its president from 1985 to 1986. Mr. Dugan received an M.B.A. from Boston University in 1964.
Lurker, Nancy Ms. Nancy Lurker is Chief Executive Officer and Director of PDI, Inc., effective November 18, 2008. Previously Ms. Lurker was Senior Vice-President and Chief Marketing Officer for Novartis Pharmaceuticals Corporation (the U.S. subsidiary of Novartis AG), where she oversaw a product portfolio in multiple therapeutic areas representing multi-billion dollars in annual sales. While at Novartis she launched numerous products including Exforge(R), Tekturna(R), Reclast(R) and Exelon(R) Patch, as well as several marketing and productivity initiatives. Prior to Novartis she was President and CEO of ImpactRx, a privately owned company offering among its services the evaluation of the impact of pharmaceutical promotion on the prescribing behavior of the nation's highest prescribing physicians. As Group Vice President-Global Primary Care Products for Pharmacia Corporation, Ms. Lurker led a multi-billion dollar business unit that produced drugs for urology, cardiovascular, central nervous system, respiratory and women's health. She was also a member of Pharmacia's U.S. Executive Management Committee, the group responsible for managing all U.S.-based profits as well as all U.S. management policies. She managed the marketing of several of the company's billion-dollar drugs, including Detrol(R) and Ambien(R). Earlier in her career, she was Vice President for Business Development at National Physicians Corporation, an IPA risk management and practice management group. During her 14 years at Bristol-Myers Squibb, Ms. Lurker rose from Senior Sales Representative at Mead Johnson to various product management and business development positions, ultimately becoming Senior Director-Worldwide Cardiovascular Franchise Management. Ms. Lurker received a Bachelor of Science in Biology and Chemistry with high honors from Seattle Pacific University, and an MBA from the University of Evansville in Evansville, Ind.
Smith, Jeffrey Mr. Jeffrey E. Smith is Chief Financial Officer, Executive Vice President, Treasurer of PDI Inc since May 2006. Immediately prior to joining PDI, Mr. Smith was senior vice president, finance and chief financial officer of Pliva, Inc., a specialty generic pharmaceutical company. From 1985 to 2002, Mr. Smith served in various executive positions with Alpharma, Inc., a global specialty pharmaceutical company. While with Alpharma, Inc., Mr. Smith was executive vice president, finance and chief financial officer and, for a three-year period, was responsible for worldwide operations while serving as acting president and member of the office of the chief executive. Mr. Smith is Certified Public Accountant who began his career with Coopers & Lybrand, now PricewaterhouseCoopers. Mr. Smith received his B.S. from Fairleigh Dickinson University.
Drazner, Howard Mr. Howard Drazner is President, Pharmakon Business unit of PDI Inc since September 2007. Prior to that, Mr. Drazner spent 10 years as senior vice president of Pharmakon (formerly known as C. Beck) where he was responsible for sales and marketing of interactive peer programs. Mr. Drazner began his career in the pharmaceutical industry with Stuart Pharmaceuticals, a division of ICI Americas, now known as AstraZeneca. In addition, he has worked in a number of sales, marketing and management positions, including advertising space sales for the American College of Surgeons and direct marketing sales, management and marketing for Buckley Dement, an American Medical Association franchisee. Mr. Drazner received a B.S. in Life Sciences from the University of Wisconsin.
Micali, Richard Mr. Richard P. Micali is Senior Vice President - Sales Services of PDI, Inc since February 2009. Prior to joining PDI, Mr. Micali spent 25 years at Bristol-Myers Squibb where he held positions of increasing responsibility in sales, marketing and managed markets. He began his career as a sales representative and most recently was vice president, oncology sales. Mr. Micali has broad sales leadership experience across several therapeutic areas and customer channels. He has extensive experience building and sales organizations while developing and retaining people. Throughout his career, he has successfully launched a variety of new products and indications. Mr. Micali is a member of the Board of Trustees for Mercer Street Friends, a non-profit organization. He received his B.S. from Bowling Green State University and an M.B.A. from John Carroll University.
Kerr, David Mr. David E. Kerr is Senior Vice President - Business Development of PDI, Inc since April 2009. Prior to joining PDI, Mr. Kerr was senior vice president of commercial business at Endo Pharmaceuticals, Inc., where he was responsible for branded and generic pharmaceutical product sales, marketing, managed markets, portfolio and strategic planning and analytics since 2006. From 2001 to 2006, Mr. Kerr served as vice president of business development at Endo Pharmaceuticals, responsible for product licensing and acquisition activities. Prior to that, Mr. Kerr spent six years at Knoll Pharmaceuticals, which was at that time a division of BASF Corporation, where he was senior director of the pain management business unit with responsibility for sales, marketing and business development activity. Also while at Knoll, Kerr served as director of sales operations and strategic planning. Prior to that, Mr. Kerr worked with American Cyanamid in international agricultural chemicals marketing. Mr. Kerr also spent 15 years with the DuPont Company in roles of increasing responsibility within the commercial side of DuPont’s life science business. Mr. Kerr received a B.S. in Accounting from Pennsylvania State University and an M.B.A. from the University of Delaware.
Belle, Gerald Mr. Gerald Belle has been appointed as Lead Independent Director of PDI, Inc effective July 30, 2009. He has served as Director of PDI Inc since April 2008. From 2004 until his retirement in November 2007, Mr. Belle served as Executive Chairman of Merial Ltd., a global animal health company that is a joint venture between sanofi-aventis and Merck & Co. Prior to that, Mr. Belle served as President and Chief Executive Officer, North America Pharmaceuticals for Aventis, Inc. from 2000 to 2004, where he successfully managed the North American merger of Rhone-Poulenc S.A. and Hoechst AG. Mr. Belle is a member of the board of directors of Myriad Genetics, Inc., a publicly held biopharmaceutical company. Mr. Belle earned a B.S.B.A. in Marketing from Xavier University in 1968 and an Master of Business Administration from Northwestern University in 1969.
Pietruski, John Mr. Pietruski is Director of PDI Inc since May 1998. From 1990 to April 2008, Mr. Pietruski was the chairman of the board of Encysive Pharmaceuticals, Inc., a pharmaceutical research and development company. He is a retired chairman of the board and chief executive officer of Sterling Drug Inc., where he was employed from 1977 until his retirement in 1988. Mr. Pietruski is a member of the board of directors of Xylos Corporation and TrialCard, Inc. Mr. Pietruski graduated Phi Beta Kappa with a B.S. in business administration with honors from Rutgers University in 1954.
Vecsi, Jan Ms. Vecsi is Director of PDI Inc since May 1998. Ms. Vecsi was employed by Citibank, N.A. from 1967 to 1996 when she retired. Starting in 1984, she served as the senior human resources officer and vice president of the Citibank Private Bank. Ms. Vecsi received a B.A. in Psychology and Elementary Education from Immaculata College in 1965.
Federspiel, John Mr. Federspiel is Director of PDI Inc since October 2001. Mr. Federspiel is president of Hudson Valley Hospital Center, a 128 bed, short-term, acute care, not-for-profit hospital in Westchester County, New York. Prior to joining Hudson Valley Hospital in 1987, Mr. Federspiel spent an additional 10 years in health administration, during which he held a variety of executive leadership positions. Mr. Federspiel has served as an appointed Member of the State Hospital Review and Planning Council, and has served as chairman of the Northern Metropolitan Hospital Association, as well as other affiliations. Mr. Federspiel received a B.S. degree from Ohio State University in 1975 and an M.B.A. from Temple University in 1977.
Ryan, Frank Mr. Ryan is Director of PDI Inc since November 2002. Mr. Ryan was a director of Digene Corporation from June 2005 until its acquisition by Qiagen N.V. in July 2007. Mr. Ryan’s career includes a 38-year tenure with Johnson & Johnson. Mr. Ryan retired in 2001 as Johnson & Johnson’s company group chairman with responsibility for worldwide Ethicon franchises and Johnson & Johnson Canada. In addition, Mr. Ryan was a member of the Medical Devices and Diagnostics Operating Group and Leader for the Group in Process Excellence (Six Sigma) and IT. Throughout his years at Johnson & Johnson, Mr. Ryan held positions of increasing responsibility, including worldwide president of Chicopee, president of Johnson and Johnson Hospital Services Co. and president of Ethicon, Inc. Mr. Ryan received a B.S. degree in mechanical engineering from the Illinois Institute of Technology in 1965 and an M.B.A. from the University of Chicago Graduate School of Business in 1969.
Curti, Joseph Dr. Curti became is Director of PDI Inc sinc August 2003. Dr. Curti was president and chief executive officer of Ferring Pharmaceuticals in Tarrytown, New York from 1995 to 1998. He previously held the position of president and chief executive officer of Neurochem, Inc. in Kingston, Ontario and president of North American Operations of Searle in Skokie, Illinois. He spent 19 years at Pfizer in a number of senior positions, both domestically and internationally, directing clinical drug development, drug regulatory, licensing and marketing activities. Dr. Curti received a B.S. from St. Joseph’s University in Philadelphia in 1959 and an M.D. from Thomas Jefferson University in Philadelphia in 1963.
Sullivan, Stephen Mr. Sullivan is Director of PDI Inc since September 2004. Mr. Sullivan is president and chief executive officer of Harlan Sprague Dawley, Inc., a privately held global provider of preclinical research tools and services. Prior to joining Harlan in 2006, Mr. Sullivan was a senior vice president of Covance, Inc. and the president of Covance Central Laboratories, Inc., a division of Covance. Prior to joining Covance, Mr. Sullivan was chairman and chief executive officer of Xenometrix, Inc., a biotechnology company with proprietary gene expression technology. He successfully merged Xenometrix with Discovery Partners International. Prior to his work with Xenometrix, Mr. Sullivan was vice president and general manager of a global diagnostic sector of Abbott Laboratories. Mr. Sullivan graduated from the University of Dayton, was a commissioned officer in the Marine Corps, and completed his M.B.A. in Marketing and Finance at Rutgers University.
Stover, Jack Mr. Stover is Director of PDI Inc since August 2005. Mr. Stover joined Antares Pharma in July 2004 as president and chief operating officer, and in August 2004 he was named chief executive officer, president and director. Mr. Stover is also a member of the board of directors of Arbios Systems Inc. Mr. Stover was previously executive vice president and chief financial officer of Sicor, Inc., a publicly held injectable pharmaceutical company, which was acquired by Teva Pharmaceutical Industries. Prior to that, Mr. Stover was executive vice president and director of a proprietary women’s pharmaceutical company, Gynetics, Inc., and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company. For more than five years, Mr. Stover was a partner with PricewaterhouseCoopers, working in their bioscience industry division in New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.
Lubatkin, Veronica Ms. Veronica Lubatkin is Director of PDI, Inc., effective November 18, 2008. From 2007 to March 2009, Ms. Lubatkin was executive vice president and chief financial officer of Par Pharmaceutical Companies, Inc. and previously served as Par Pharmaceutical Companies’ vice president and controller. Prior to joining Par Pharmaceutical Companies in April 2006, Ms. Lubatkin served in various positions at Schering-Plough Corporation from 1997 through 2006, most recently as executive director of strategic alliances for the cholesterol joint venture between Schering-Plough and Merck and prior to that as senior director of finance for Schering-Plough’s global animal health business. Prior to joining Schering-Plough, Ms. Lubatkin was finance director for Neuman Distributors, Inc., formerly a U.S. pharmaceutical wholesaler. She began her career with Arthur Anderson in 1985. Ms. Lubatkin earned a B.A. degree in Accounting from Pace University in 1985 and is a Certified Public Account.

Basic Compensation

Name Fiscal Year Total
Dugan, John 136,760
Lurker, Nancy 212,295
Smith, Jeffrey 763,443
Drazner, Howard 355,528
Micali, Richard --
Kerr, David --
Belle, Gerald --
Pietruski, John --
Vecsi, Jan --
Federspiel, John --
Ryan, Frank --
Curti, Joseph --
Sullivan, Stephen --
Stover, Jack --
Lubatkin, Veronica --
As Of 30 Dec 2008

Insider Trading

Name Shares Traded Price
SMITH JEFFREY E 2,500 $5.25
LURKER NANCY 6,000 $5.17
LURKER NANCY 3,960 $5.05
BELLE GERALD P 1,000 $5.21
PIETRUSKI JOHN M 12,262 $3.67
RYAN FRANK J 12,262 $3.67
STOVER JACK E 12,262 $3.67
SULLIVAN STEPHEN J 12,262 $3.67
LUBATKIN VERONICA 12,262 $3.67
FEDERSPIEL JOHN 12,262 $3.67
BELLE GERALD P 12,262 $3.67
VECSI JAN MARTENS 12,262 $3.67
CURTI JOSEPH I 12,262 $3.67
VECSI JAN MARTENS 300 $3.33
VECSI JAN MARTENS 1,500 $3.47
VECSI JAN MARTENS 1,500 $3.30
VECSI JAN MARTENS 1,700 $3.34
SMITH JEFFREY E 17,827 $5.89
SMITH JEFFREY E 50,000 $4.00
RYAN FRANK J 6,000 $4.00
VECSI JAN MARTENS 900 $3.63
FEDERSPIEL JOHN 1,400 $3.90
FEDERSPIEL JOHN 100 $3.70
VECSI JAN MARTENS 4,300 $3.76
FEDERSPIEL JOHN 100 $3.86
» Full list on Insider Trading
view people for: